Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Antiinfective agent stubs
Ponazuril
Другие языки:

    Ponazuril

    Подписчиков: 0, рейтинг: 0
    Ponazuril
    Ponazuril.png
    Clinical data
    Trade names Marquis
    AHFS/Drugs.com FDA Professional Drug Information
    Routes of
    administration    		 Oral
    ATCvet code
    Legal status
    Legal status
    Identifiers
    • 1-Methyl-3-[3-methyl-4-[4-(trifluoromethylsulfonyl)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    CompTox Dashboard (EPA)
    ECHA InfoCard 100.157.907
    Chemical and physical data
    Formula C18H14F3N3O6S
    Molar mass 457.38 g·mol−1
    3D model (JSmol)
    • CC1=C(C=CC(=C1)N2C(=O)NC(=O)N(C2=O)C)OC3=CC=C(C=C3)S(=O)(=O)C(F)(F)F
    • InChI=1S/C18H14F3N3O6S/c1-10-9-11(24-16(26)22-15(25)23(2)17(24)27)3-8-14(10)30-12-4-6-13(7-5-12)31(28,29)18(19,20)21/h3-9H,1-2H3,(H,22,25,26) ☒N
    • Key:VBUNOIXRZNJNAD-UHFFFAOYSA-N ☒N
     ☒NcheckY (what is this?)  (verify)

    Ponazuril (INN), sold by Merial, Inc., now part of Boehringer Ingelheim, under the trade name Marquis® (15% w/w ponazuril), is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by coccidia Sarcocystis neurona. More recently, veterinarians have been preparing a formulary version of the medication for use in small animals such as cats, dogs, and rabbits against coccidia as an intestinal parasite. Coccidia treatment in small animals is far shorter than treatment for EPM.

    See also



    Новое сообщение